Duyuru • May 07
Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year Ending December 31, 2026 Tactile Systems Technology, Inc. updated earnings guidance for the full year ending December 31, 2026. For the period, the company expects total revenue in the range of $360 million to $368 million, representing growth of approximately 9% to 12% year-over-year, compared to total revenue of $329.5 million in 2025. The Company’s prior 2026 guidance expectation was total revenue in the range of $357 million to $365 million, representing growth of approximately 8% to 11% year-over-year. Net income in the range of $24,697,000 to $26,137,000. Duyuru • Apr 21
Tactile Systems Technology, Inc. to Report Q1, 2026 Results on May 04, 2026 Tactile Systems Technology, Inc. announced that they will report Q1, 2026 results After-Market on May 04, 2026 Duyuru • Mar 10
Tactile Systems Technology, Inc. Announces Appointment of Andrea A. Pearson to Board of Directors and Member of the Compliance and Reimbursement Committee and of the Nominating and Corporate Governance Committee, Effective March 9, 2026 On March 4, 2026, the board of directors of Tactile Systems Technology, Inc. announced the appointment of Andrea Pearson to the Company’s Board of Directors (“Board”) and as a member of the Compliance & Reimbursement and Nominating & Corporate Governance Committees, effective March 9, 2026. Ms. Pearson is an accomplished senior executive and growth strategist with deep expertise in scaling healthcare organizations. Her extensive experience spans more than 25 years and includes exposure to product development, customer acquisition, branding, marketing communications, and public relations. Most recently, she served as Growth Advisor and Chief Marketing Officer at Harbor Health, a healthcare organization that integrates clinical care with health insurance coverage. Previously, she was Chief Growth Officer, and, before that, Chief Marketing Officer at DispatchHealth, a leader in at-home, hospital-level care, where she architected the company’s growth strategy, scaling the business from two to more than 50 U.S. markets while driving a 30x increase in revenue. Prior to DispatchHealth, Ms. Pearson held multiple executive roles at HealthGrades, a leading online platform connecting patients with healthcare providers, including Chief Marketing Officer and Executive Vice President and General Manager. As Chief Marketing Officer, she grew the consumer audience from one million monthly to one million daily visitors. Her earlier career experience includes 10 years of increasing responsibility across product development, marketing, and general management roles. Duyuru • Feb 19
Tactile Systems Technology, Inc., Annual General Meeting, May 06, 2026 Tactile Systems Technology, Inc., Annual General Meeting, May 06, 2026. Duyuru • Feb 04
Tactile Systems Technology, Inc. to Report Q4, 2025 Results on Feb 17, 2026 Tactile Systems Technology, Inc. announced that they will report Q4, 2025 results at 4:00 PM, US Eastern Standard Time on Feb 17, 2026 Duyuru • Nov 05
Tactile Systems Technology, Inc. Updates Earning Guidance for the Full Year 2025 Tactile Systems Technology, Inc. updated earning guidance for the full year 2025. For the period, the total revenue in the range of $317 million to $321 million, representing growth of approximately 8% to 10% year-over-year, compared to total revenue of $293.0 million in 2024. The Company’s prior 2025 guidance expectation was total revenue in the range of $310 million to $315 million, representing growth of approximately 6% to 8% year-over-year. Duyuru • Nov 04
Tactile Systems Technology, Inc. (NasdaqGM:TCMD) announces an Equity Buyback for $25 million worth of its shares. Tactile Systems Technology, Inc. (NasdaqGM:TCMD) announces an share repurchase program. Under the program, the company will repurchase up to $25 million worth of its common stock. The program will be financed via existing cash and future cash flows. The repurchase program is valid till November 3, 2027. Duyuru • Oct 30
Tactile Systems Technology, Inc. Announces the Presentation of New Six-Month Clinical Data Tactile Systems Technology, Inc. announced the presentation of new six-month clinical data during the late-breaking poster session at the American Congress of Rehabilitation Medicine (ACRM) 102nd Annual Fall Conference demonstrating sustained clinical benefits of Flexitouch®? Plus as a first-line therapy for treating patients with head and neck cancer-related lymphedema. The six-month analysis, drawn from a large randomized controlled trial, showed improvement in lymphedema symptom burden for participants in both the advanced pneumatic compression device (APCD) study arm, consisting of treatment with Flexitouch Plus, and the usual care study arm, which included therapist-guided multimodal treatment. Symptom severity was based on scoring from disease-specific patient-reported symptom surveys. Welling improvements were also observed in objective clinical assessments, including CT imaging. Highlights from the six-month results include: Flexitouch Plus demonstrated reduced internal swelling at the majority of anatomical sites (13 of 19), with statistically significant improvement achieved in the base of tongue (p=0.008) and arytenoids (p=0.023); Clinician-reported outcome measures of both internal (Endoscopy Modified Patterson Scale) and external soft tissue swelling favored Flexitouch Plus over usual care; Significant improvement in epiglottic thickness and prevertebral soft tissue thickness at C3 in both groups at six months; The initial patient benefit of Flexitouch Plus and usual care was maintained over the six-month study timeframe; and Both groups demonstrated sustained improvement in symptom burden over the six-month study period. The new long-term results follow two-month data released at ASCO in June 2025 and are drawn from the largest prospective, randomized controlled study ever conducted among head and neck cancer survivors in the United States, which enrolled 236 patients across 10 academic and community-based centers. The sustained patient benefits associated with Flexitouch Plus, as demonstrated in the six-month results, combined with the early improvements seen at two months, are clinically important for head and neck lymphedema patients and the providers who treat them. Not only is therapist-guided care limited in the U.S., but payer coverage policies have restricted access to Flexitouch Plus in this population. Duyuru • Oct 21
Tactile Systems Technology, Inc. to Report Q3, 2025 Results on Nov 03, 2025 Tactile Systems Technology, Inc. announced that they will report Q3, 2025 results After-Market on Nov 03, 2025 Duyuru • Aug 07
Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year 2025 Tactile Systems Technology, Inc. updated earnings guidance for the full year 2025. For the period, Company now expects total revenue in the range of $310 million to $315 million, representing growth of approximately 6% to 8% year-over-year, compared to total revenue of $293.0 million in 2024. The Company’s prior 2025 guidance expectation was total revenue in the range of $309 million to $315 million, representing growth of approximately 5% to 8% year-over-year. Duyuru • Jul 22
Tactile Systems Technology, Inc. to Report Q2, 2025 Results on Aug 04, 2025 Tactile Systems Technology, Inc. announced that they will report Q2, 2025 results After-Market on Aug 04, 2025 Duyuru • Jun 04
Tactile Systems Technology, Inc. Announces the Presentation of New Clinical Data at the American Society of Clinical Oncology 2025 Annual Meeting Tactile Systems Technology, Inc. announced the presentation of new clinical data at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting that demonstrates significant clinical and quality-of-life benefits associated with use of the Company's Flexitouch Plus versus usual care in treating patients with head and neck cancer-related lymphedema. The two-month analysis featured data from the Company's six-month clinical trial, which examines the effectiveness of Flexitouch Plus, an advanced pneumatic compression device (APCD), versus usual care in treating head and neck cancer survivors. The study includes 236 subjects across 10 academic and community sites, representing the largest prospective, randomized controlled study on this patient group ever conducted in the United States. Outcome measures include changes in disease-specific patient-reported symptom survey scores and objective clinical assessments, including CT imaging. Two-month data demonstrated that usual care and APCD are similarly effective treatment modalities for head and neck lymphedema. Specific areas of differentiation showed: Usual care participants took an average of 29.8 days to begin therapist guided lymphedema treatment (TGLT), while APCD participants received their device in 17.9 days; Of participants randomized to usual care, only 71% received TGLT compared to 94.9% of those in the APCD group; APCD participants had significant reduction in swelling via digital photography and total Head and Neck Cancer Related Lymphedema and Fibrosis Grading (HN-LEFG) scores while usual care participants exhibited incremental improvements; and Self-reported symptom improvement occurred in both groups, with APCD demonstrating significant improvement on three of the six health-related quality-of-life sub scales. Flexitouch Plus is an FDA-cleared therapy designed for at-home treatment of lymphedema, chronic venous insufficiency (CVI), and chronic wounds. Duyuru • May 07
Tactile Systems Technology, Inc. Updates Financial Guidance for Full Year Ending December 31, 2025 Tactile Systems Technology, Inc. updated financial guidance for full year ending December 31, 2025. For the period, the company expects total revenue in the range of $309 million to $315 million representing growth of approximately 5% to 8% year-over-year, compared to total revenue of $293.0 million in 2024. The Company’s prior 2025 guidance expectation was total revenue in the range of $316 million to $322 million, representing growth of approximately 8% to 10% year-over-year. The company expects Net income to be in the range of $13,400,000 to $14,800,000. Duyuru • Apr 22
Tactile Systems Technology, Inc. to Report Q1, 2025 Results on May 05, 2025 Tactile Systems Technology, Inc. announced that they will report Q1, 2025 results After-Market on May 05, 2025 Duyuru • Mar 31
Tactile Systems Technology, Inc., Annual General Meeting, May 07, 2025 Tactile Systems Technology, Inc., Annual General Meeting, May 07, 2025. Location: wells fargo center, suite 2200, 90 south seventh st, minnesota 55402., minneapolis United States Duyuru • Feb 19
Tactile Systems Technology, Inc. Provides Earnings Guidance for the Year Ending December 31, 2025 Tactile Systems Technology, Inc. provided earnings guidance for the year ending December 31, 2025. The Company expects full year 2025 total revenue in the range of $316 million to $322 million, representing growth of approximately 8% to 10% year-over-year, compared to total revenue of $293.0 million in 2024. The company expects Net income to be in the range of $15,750,000 to $17,150,000. Duyuru • Feb 06
Tactile Systems Technology, Inc. to Report Q4, 2024 Results on Feb 18, 2025 Tactile Systems Technology, Inc. announced that they will report Q4, 2024 results After-Market on Feb 18, 2025 Duyuru • Feb 04
Tactile Medical Expands Launch of Nimbl to Include Patients with Lower Extremity Lymphedema Tactile Systems Technology, Inc. announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States (U.S.) for the treatment of both upper and lower extremity lymphedema. Nimbl's expanded availability to include lower extremity conditions ("phlebolymphedema") follows its commercial introduction in October 2024, initially focused on treating patients suffering from upper extremity lymphedema". Nimbl is the smallest pneumatic compression device (PCD) of its kind, featuring a compact controller that is 68% lighter and 40% smaller than the Company's current generation PCD. The lower extremity garment uses 94% lessosing, making the device easy to transport and manage. Nimbl is the only basic PCD with Bluetooth®? connectivity, providing patients a way to track their treatments and symptom progress with the Company's free Kylee™? digital application. Duyuru • Jan 13
Tactile Systems Technology, Inc. Announces the Appointment of Laura King to the Board of Directors and as A Member of the Audit and Compliance & Reimbursement Committees Tactile Systems Technology, Inc. announced the appointment of Laura King to the Company’s Board of Directors (“Board”) and as a member of the Audit and Compliance & Reimbursement Committees, effective January 13, 2025. Ms. King is a seasoned healthcare executive with a proven track record of leadership and developing innovative products that enhance patient care. Her extensive experience includes a 22-year career at General Electric Company (GE), where she served as a Company Officer in her role as President & CEO of GE Healthcare’s Global Interventional Business, which provided clinical solutions enabling minimally invasive procedures in cardiology, interventional radiology, and surgery. Her earlier experience at GE included various senior level audit and finance roles, including Chief Information Officer & Chief Financial Officer, Consumer & ECM Motors. Ms. King is currently co-founder & CEO of BiaCure, Inc., a developer of effective treatments for nail fungus. Previously, she co-founded and served as CEO of Elucent Medical, a developer of a real-time surgical navigation platform that has positively impacted over 10,000 breast cancer patients. Ms. King also served as President & CEO of NeuWave Medical, a manufacturer and marketer of a minimally invasive soft tissue microwave ablation system to destroy tumor cells, which was acquired by Johnson & Johnson’s MedTech division. Duyuru • Nov 06
Tactile Systems Technology, Inc. (NasdaqGM:TCMD) announces an Equity Buyback for $30 million worth of its shares. Tactile Systems Technology, Inc. (NasdaqGM:TCMD) announces an share repurchase program. Under the program, the company will repurchase up to $30 million worth of its common stock. The program will be financed via existing cash and cash equivalents and future cash flows. The repurchase program is valid till October 31, 2026. Duyuru • Nov 05
Tactile Systems Technology, Inc. Revises Revenue Guidance for the Year 2024 Tactile Systems Technology, Inc. revised revenue guidance for the year 2024. The Company is updating its 2024 financial outlook and now expects full year 2024 total revenue in the range of $292 million to $295 million, representing growth of approximately 6% to 8% year-over-year, compared to total revenue of $274.4 million in 2023. The Company’s prior 2024 guidance expectation was total revenue in the range of $293 million to $298 million, representing growth of approximately 7% to 9%. Duyuru • Oct 22
Tactile Systems Technology, Inc. to Report Q3, 2024 Results on Nov 04, 2024 Tactile Systems Technology, Inc. announced that they will report Q3, 2024 results After-Market on Nov 04, 2024 Duyuru • Oct 02
Tactile Systems Technology, Inc. Launches Next-Generation Nimbl™ Lymphedema Platform Tactile Systems Technology, Inc. announced that Nimbl, its next-generation pneumatic compression platform, is now commercially available throughout the United States for the treatment of upper extremity lymphedema. Nimbl, which is significantly smaller and lighter than previous device iterations, is indicated as a treatment option for patients with both upper and lower extremity lymphedema, chronic edema, venous insufficiency, and wound healing. Nimbl received U.S Food & Drug Administration (FDA) 510(k) clearance in June 2024 and Pricing, Data Analysis, and Coding (PDAC) approval from the Centers for Medicare & Medicaid Services (CMS) in September 2024. The Company expects to make Nimbl commercially available for patients with lower extremity conditions in the coming months. Nimbl is 68% lighter, 40% smaller, and uses 33% less hosing than the Company’s current generation basic pneumatic compression device (PCD). Its compact design is the smallest PCD of its kind, making it an ideal therapy for daily use at home or on the go. In addition to the patient centric feature enhancements, Nimbl also offers connectivity to the Company’s free Kylee™ digital application, providing patients a simple way to track their usage and change in symptoms, and to share results with their care team. Convenient accessories are available for purchase including a rechargeable battery and custom-designed travel bag. Duyuru • Sep 16
Tactile Medical Receives PDAC Approval for Nimbl Lymphedema Platform Tactile Systems Technology, Inc. announced that the Pricing, Data Analysis, and Coding (PDAC) contractor for the Centers for Medicare & Medicaid Services (CMS) has approved the use of Healthcare Common Procedure Coding System (HCPCS) code E0651 for billing the Durable Medical Equipment Medicare Administrative Contractors for Nimbl, the Company’s next-generation pneumatic compression platform. PDAC approval is subsequent to the receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) in June 2024. The Company will make Nimbl commercially available in the United States in the coming weeks. Nimbl is the next generation of the Company’s basic lymphedema compression solution and is indicated for the treatment of lymphedema, chronic edema, venous insufficiency, and wound healing. The device features several key patient-friendly enhancements over prior generations, including a 40% and 68% reduction in size and weight, respectively, making it more portable and ideal for active lifestyles. Nimbl offers connectivity to the Company’s Kylee digital application, enabling patients to actively track their therapy progress and share results with their care team. Duyuru • Jul 23
Tactile Systems Technology, Inc. to Report Q2, 2024 Results on Aug 05, 2024 Tactile Systems Technology, Inc. announced that they will report Q2, 2024 results After-Market on Aug 05, 2024 Reported Earnings • May 08
First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2024 results: US$0.093 loss per share (further deteriorated from US$0.089 loss in 1Q 2023). Revenue: US$61.1m (up 3.8% from 1Q 2023). Net loss: US$2.21m (loss widened 17% from 1Q 2023). Revenue exceeded analyst estimates by 3.1%. Earnings per share (EPS) missed analyst estimates by 16%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Duyuru • Apr 16
Tactile Systems Technology, Inc. to Report Q1, 2024 Results on May 06, 2024 Tactile Systems Technology, Inc. announced that they will report Q1, 2024 results After-Market on May 06, 2024 Duyuru • Mar 28
Tactile Systems Technology, Inc., Annual General Meeting, May 08, 2024 Tactile Systems Technology, Inc., Annual General Meeting, May 08, 2024, at 09:00 Central Daylight. Location: Wells Fargo Center 90 South Seventh St., Ste 2200 Mineapolis Minnesota United States Agenda: To elect eight directors; to ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the year ending December 31, 2024; to approve, on an advisory basis, the 2023 compensation of our named executive officers as disclosed in the accompanying Proxy Statement; to approve an amendment to our Amended and Restated Certificate of Incorporation to allow for exculpation of officers as permitted by Delaware law; and to transact such other business as may properly come before the meeting or at any and all adjournments or postponements thereof. Valuation Update With 7 Day Price Move • Feb 28
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to US$15.97, the stock trades at a forward P/E ratio of 28x. Average trailing P/E is 36x in the Medical Equipment industry in the US. Total loss to shareholders of 67% over the past three years. Major Estimate Revision • Feb 27
Consensus EPS estimates increase by 16%, revenue downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from US$309.2m to US$302.9m. EPS estimate rose from US$0.488 to US$0.568. Net income forecast to shrink 52% next year vs 16% growth forecast for Medical Equipment industry in the US . Consensus price target down from US$24.00 to US$20.67. Share price rose 9.3% to US$15.52 over the past week. Recent Insider Transactions Derivative • Feb 26
President notifies of intention to sell stock Daniel Reuvers intends to sell 5k shares in the next 90 days after lodging an Intent To Sell Form on the 23rd of February. If the sale is conducted around the recent share price of US$14.85, it would amount to US$80k. For the year to December 2020, Daniel's total compensation was 19% salary and 81% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2023, Daniel's direct individual holding has increased from 28.01k shares to 30.34k. Company insiders have collectively sold US$269k more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • Feb 21
Full year 2023 earnings: EPS exceeds analyst expectations Full year 2023 results: EPS: US$1.24 (up from US$0.89 loss in FY 2022). Revenue: US$274.4m (up 11% from FY 2022). Net income: US$28.5m (up US$46.4m from FY 2022). Profit margin: 10% (up from net loss in FY 2022). The move to profitability was primarily driven by higher revenue. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 11%. Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 7.9% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has fallen by 36% per year, which means it is significantly lagging earnings. Duyuru • Feb 20
Tactile Systems Technology, Inc. Provides Revenue Guidance for the Full Year 2024 Tactile Systems Technology, Inc. provided revenue guidance for the full year 2024. For the year, the company expected total revenue in the range of $300.0 million to $305.0 million, representing growth of approximately 9% to 11% year-over-year, compared to total revenue of $274.4 million in 2023. Duyuru • Jan 30
Tactile Systems Technology, Inc. to Report Q4, 2023 Results on Feb 20, 2024 Tactile Systems Technology, Inc. announced that they will report Q4, 2023 results Pre-Market on Feb 20, 2024 Valuation Update With 7 Day Price Move • Nov 13
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to US$10.71, the stock trades at a forward P/E ratio of 17x. Average forward P/E is 28x in the Medical Equipment industry in the US. Total loss to shareholders of 75% over the past three years. Reported Earnings • Nov 07
Third quarter 2023 earnings: EPS exceeds analyst expectations Third quarter 2023 results: EPS: US$0.95 (up from US$0.11 loss in 3Q 2022). Revenue: US$69.6m (up 6.6% from 3Q 2022). Net income: US$22.3m (up US$24.6m from 3Q 2022). Profit margin: 32% (up from net loss in 3Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates significantly. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings. Duyuru • Nov 07
Tactile Systems Technology, Inc. Updates Earnings Guidance for the Full Year 2023 Tactile Systems Technology, Inc. updated earnings guidance for the full year 2023. For the period, the Company expects full year 2023 total revenue in the range of $273.0 million to $277.0 million, representing growth of approximately 11% to 12% year-over-year. The Company’s prior 2023 revenue guidance expectation was total revenue in the range of $274.0 million to $278.0 million, representing growth of approximately 11% to 13% year-over-year. Price Target Changed • Oct 17
Price target decreased by 7.9% to US$27.33 Down from US$29.67, the current price target is an average from 3 analysts. New target price is 144% above last closing price of US$11.19. Stock is up 51% over the past year. The company is forecast to post earnings per share of US$0.09 next year compared to a net loss per share of US$0.89 last year. Duyuru • Oct 05
Tactile Systems Technology, Inc. to Report Q3, 2023 Results on Nov 06, 2023 Tactile Systems Technology, Inc. announced that they will report Q3, 2023 results After-Market on Nov 06, 2023 Duyuru • Aug 09
Tactile Systems Technology, Inc. Revises Earnings Guidance for the Full Year 2023 Tactile Systems Technology, Inc. revised earnings guidance for the full year 2023. For the year, the company expects total revenue in the range of $274 million to $278 million, representing growth of approximately 11% to 13% year-over-year. The Company's prior 2023 revenue guidance expectations called for total revenue in the range of $271 million to $275 million, representing growth of approximately 10% to 11.5% year-over-year. Reported Earnings • Aug 08
Second quarter 2023 earnings released: US$0.004 loss per share (vs US$0.23 loss in 2Q 2022) Second quarter 2023 results: US$0.004 loss per share (improved from US$0.23 loss in 2Q 2022). Revenue: US$68.3m (up 15% from 2Q 2022). Net loss: US$100.0k (loss narrowed 98% from 2Q 2022). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 22% per year, which means it has not declined as severely as earnings. Buying Opportunity • Jul 24
Now 22% undervalued Over the last 90 days, the stock is up 26%. The fair value is estimated to be US$28.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 11% over the last 3 years. Meanwhile, the company became loss making. Duyuru • Jul 21
Tactile Systems Technology, Inc. Announces Senior Vice President of Sales Changes Tactile Systems Technology, Inc. announced the appointment of Sherri Ferstler to the position of Senior Vice President of Sales, effective July 31, 2023. Ms. Ferstler will succeed Eric Pauls, who will be resigning from the Company, effective July 28, 2023. Prior to joining Tactile Medical, Ms. Ferstler served as Vice President Sales, North America for Johnson & Johnson Vision since 2016. In this position, Ms. Ferstler led the field & inside sales teams, strategic accounts & training functions selling Acuvue brand contact lenses across multiple channels. Ms. Ferstler began her career in 1992 with Parke-Davis Pharmaceuticals where she served in a variety of sales, sales management and training and development roles. She joined Pfizer in 2000, serving as a district sales manager for all branded pharmaceutical products until 2003, then as Director of Division Operations and as a regional manager for Pfizer’s Urology and Respiratory product portfolios. From 2007 to 2016, Ms. Ferstler led regional and national sales teams for Endo Pharmaceuticals, Bayer Diabetes Care and Mylan Pharmaceuticals. Ms. Ferstler holds Bachelor of Arts in Psychology from the State University of New York College at Buffalo. Duyuru • Jun 30
Tactile Systems Technology, Inc. to Report Q2, 2023 Results on Aug 07, 2023 Tactile Systems Technology, Inc. announced that they will report Q2, 2023 results After-Market on Aug 07, 2023 Duyuru • Jun 25
Tactile Systems Technology, Inc.(NasdaqGM:TCMD) dropped from Russell Small Cap Comp Value Index Tactile Systems Technology, Inc.(NasdaqGM:TCMD) dropped from Russell Small Cap Comp Value Index Duyuru • Jun 02
Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Tactile Systems Technology, Inc. Securities Litigation Robbins Geller Rudman & Dowd LLP announced the following update regarding the Tactile Systems Technology, Inc. Securities Litigation: that a hearing will be held on August 23, 2023, (1) the proposed settlement (the “Settlement”) of the above-captioned action as set forth in the Stipulation of Settlement (“Stipulation”)1 for $5,000,000 in cash should be approved by the Court as fair, reasonable, and adequate; (2) the Judgment as provided under the Stipulation should be entered dismissing the Litigation with prejudice; (3) to award Lead Counsel attorneys’ fees and expenses out of the Settlement Fund (as defined in the Notice of Pendency and Proposed Settlement of Class Action (“Notice”), which is discussed below), and, if so, in what amounts; and (4) the Plan of Allocation should be approved by the Court as fair, reasonable, and adequate. Recent Insider Transactions Derivative • May 15
Independent Chairman notifies of intention to sell stock William Burke intends to sell 4k shares in the next 90 days after lodging an Intent To Sell Form on the 12th of May. If the sale is conducted around the recent share price of US$21.86, it would amount to US$96k. Since June 2022, William's direct individual holding has increased from 7.43k shares to 24.44k. Company insiders have collectively sold US$212k more than they bought, via options and on-market transactions in the last 12 months. Reported Earnings • May 10
First quarter 2023 earnings: EPS and revenues exceed analyst expectations First quarter 2023 results: US$0.089 loss per share (improved from US$0.78 loss in 1Q 2022). Revenue: US$58.8m (up 23% from 1Q 2022). Net loss: US$1.89m (loss narrowed 88% from 1Q 2022). Revenue exceeded analyst estimates by 9.0%. Earnings per share (EPS) also surpassed analyst estimates by 62%. Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 25% per year, which means it has not declined as severely as earnings. Duyuru • May 09
Tactile Systems Technology, Inc. Provides Revenue Guidance for Full Year 2023 Tactile Systems Technology, Inc. provided revenue guidance for the full year 2023. For the period, the company expects total revenue in the range of approximately $271.0 million to $275.0 million, representing growth of approximately 10% to 11.5% year-over-year. The Company’s prior 2023 revenue guidance expectations called for total revenue in the range of $269.0 million to $273.0 million, representing growth of approximately 9% to 11% year-over-year. Major Estimate Revision • Apr 18
Consensus EPS estimates fall by 167% The consensus outlook for fiscal year 2023 has been updated. 2023 expected loss increased from -US$0.022 to -US$0.06 per share. Revenue forecast of US$271.8m unchanged since last update. Medical Equipment industry in the US expected to see average net income growth of 14% next year. Consensus price target down from US$24.33 to US$23.67. Share price was steady at US$17.70 over the past week. Recent Insider Transactions • Mar 05
President recently sold US$108k worth of stock On the 28th of February, Daniel Reuvers sold around 7k shares on-market at roughly US$15.20 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Daniel has been a net seller over the last 12 months, reducing personal holdings by US$117k. Breakeven Date Change • Feb 22
Forecast breakeven date moved forward to 2023 The 3 analysts covering Tactile Systems Technology previously expected the company to break even in 2024. New consensus forecast suggests the company will make a profit of US$2.22m in 2023. Earnings growth of 142% is required to achieve expected profit on schedule. Reported Earnings • Feb 22
Full year 2022 earnings: EPS and revenues exceed analyst expectations Full year 2022 results: US$0.89 loss per share (further deteriorated from US$0.60 loss in FY 2021). Revenue: US$246.8m (up 19% from FY 2021). Net loss: US$17.9m (loss widened 51% from FY 2021). Revenue exceeded analyst estimates by 1.4%. Earnings per share (EPS) also surpassed analyst estimates by 8.2%. Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 7.5% growth forecast for the Medical Equipment industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 46 percentage points per year, which is a significant difference in performance. Duyuru • Feb 02
Tactile Systems Technology, Inc. to Report Q4, 2022 Results on Feb 21, 2023 Tactile Systems Technology, Inc. announced that they will report Q4, 2022 results Pre-Market on Feb 21, 2023 Duyuru • Jan 06
Tactile Systems Technology, Inc. Appoints Carmen Volkart to Board of Directors Tactile Systems Technology, Inc. announced the appointment of Carmen Volkart to the Company’s Board of Directors (“Board”), effective January 5, 2023. Since 2018, Carmen Volkart has served as the Chief Financial Officer of NatureWorks LLC, a privately-held advanced materials company and developer of renewably sourced polymers and chemicals. Prior to joining NatureWorks, she served as the Chief Financial Officer of NxThera, Inc., a privately-held medical device company focused on the treatment of benign prostatic hyperplasia, from 2012 until its acquisition by Boston Scientific in 2018. From 2010 to 2012, Ms. Volkart served as Chief Financial Officer of Tornier, N.V., a medical device company focused on treating musculoskeletal injuries and disorders of the shoulder, elbow, wrist, hand, ankle and foot. She led Tornier through a successful initial public offering in 2011. Prior to joining Tornier, Ms. Volkart served as Chief Operating and Financial Officer, Corporate Secretary, Compliance Officer and Treasurer of Spine Wave, Inc., a privately-held medical device company focused on minimally invasive spine surgery and expandable interbody devices, from 2006 to 2010. From 2004 to 2006, Ms. Volkart served as Executive Vice President, and Chief Financial Officer of American Medical Systems, Inc., a publicly traded medical device company focused on male and female pelvic health. Her career history also includes significant experience in various financial and managerial positions at both Medtronic, Inc., from 1992 to 2004, and Honeywell, Inc., from 1982 to 1992. Price Target Changed • Nov 16
Price target decreased to US$23.33 Down from US$30.00, the current price target is an average from 3 analysts. New target price is 176% above last closing price of US$8.45. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$0.97 next year compared to a net loss per share of US$0.60 last year. 
